Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Research issues and strategies for genomic and proteomic biomarker discovery and validation: a statistical perspective.

Pharmacogenomics - 1 Sept 2004

Feng Ziding, Prentice Ross, Srivastava Sudir

Abstract excerpt

The development and validation of clinically useful biomarkers from high-dimensional genomic and proteomic information pose great research challenges. Present bottlenecks include: that few of the biomarkers showing promise in initial discovery were found to warrant subsequent validation; and biomarker validation is expensive and time consuming. Biomarker evaluation should proceed in an orderly fashion to enhance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Gene Expression Profiling
Share to Genetic Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genomics

Share to Genotype

Share to Neoplasms

Share to Proteomics

Share to Quality Control

Source

Identifiers

PMID: 15335291
DOI: 10.1517/14622416.5.6.709

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Research issues and strategies for genomic and proteomic biomarker discovery and validation: a statistical perspective.PMID 15335291Read ↗

The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline.Semantic proximity Read ↗

Statistical and practical considerations for clinical evaluation of predictive biomarkers.Semantic proximity Read ↗

Cancer biomarker discovery and validation.Semantic proximity Read ↗

In Pursuit of Greater Reproducibility and Credibility of Early Clinical Biomarker ResearchSemantic proximity Read ↗

Study Design Considerations for Cancer Biomarker DiscoveriesSemantic proximity Read ↗

Delivery of High‐Quality Biomarker AssaysSemantic proximity Read ↗

A hierarchical Bayes model for biomarker subset effects in clinical trialsSemantic proximity Read ↗

Prospective–Retrospective Biomarker Analysis for Regulatory Consideration: white Paper from the Industry Pharmacogenomics Working GroupSemantic proximity Read ↗

The promise of biomarkers in cancer screening and detection.Semantic proximity Read ↗

Revisiting the standard blueprint for biomarker development to address emerging cancer early detection technologiesSemantic proximity Read ↗

Translating genomic biomarkers into clinically useful diagnostics.Semantic proximity Read ↗

Continuous Biomarker Assessment by Exhaustive Survival AnalysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.